Pluripotent Cells

Pluripotent Cells Portfolios

Most Recent Inventions

Xeno-Free Protocol for Generating Endothelial Cells from Human Pluripotent Stem Cells

UW–Madison researchers have developed a fully defined and xenogenic material-free method of producing and expanding clinically relevant human ECs for therapeutic and tissue modelling applications. Populations of up to 80 percent CD31+ ECs are generated from both human embryonic and induced pluripotent stem cells.

Like existing protocols, the new method uses factors including Bone Morphogenetic Protein (BMP), Activin A and a TGF-Beta 1 inhibitor.

Human Pluripotent Stem Cell-Based Models for Neural Toxicity Screening

UW–Madison researchers have developed 3-D vascularized neuronal tissue models for screening neurotoxic agents. The new constructs are highly uniform and the first to contain every major component of the developing brain: neuronal cells (GABAergic and Glutamatergic), glial cells (astrocytes and oligodendrocytes), interconnected vasculature and mature microglia.

Combined with the modular nature of tunable hydrogels and the power of machine learning tools, the new testing platform enables large-scale, quantitative throughput applications.

Generating Human Heart Cells via Lineage Reprogramming

UW–Madison researchers have developed a method to reprogram human (or other mammalian) somatic cells to iCPCs by defined factors. The factors include several early cardiac transcription factors and a chromatin remodeling factor. They may be introduced into the cell via standard vector techniques. Successfully reprogrammed cells are separated from the others and cultured in a proliferative state.

Generating Hindbrain and Spinal Cord Cells from Human Stem Cells

UW–Madison researchers have developed a culture medium for producing neural cell populations (caudal lateral epiblasts, posterior neuroectoderm, posterior neuroepithelial cells or motor neurons) with desired positional identity within the hindbrain or spinal cord. This identity can be predicted a priori in a fully defined and scalable way based on HOX gene expression.

The culture medium is composed of standard ingredients and includes a fibroblast growth factor and an activator of β-catenin pathway signaling.

Most Recent Patents

Hydrogel Arrays for Screening Cell-Substrate Interactions

UW–Madison researchers developed a new method for forming patterned hydrogel arrays featuring any number of test spots possessing different characteristics, such as shape and chemical composition. The arrays can be used to culture a range of cell types and rapidly analyze their behavior (e.g., attachment, spreading, proliferation and differentiation).

The arrays are prepared using a hydrogel precursor solution containing a polymer and crosslinker. The solution is sandwiched between stenciled SAM layers containing hydrophilic (‘water-loving’) and hydrophobic (‘water-hating’) regions, then polymerized and released.

As a result of the process, the array features hydrophilic spots surrounded and isolated by hydrophobic regions, preventing any mixing of contents. The spots can have any desired shape, size and chemical composition.

Mesenchymal Stem Cell-Educated Macrophages to Treat Radiation Damage and More

UW–Madison researchers have discovered that mesenchymal stem cell-educated macrophages (MEMs) have potent tissue regenerative properties that can minimize tissue damage from radiation and increase survival in clinically significant ways.

They have demonstrated in a relevant preclinical model that their new method is much superior to other forms of cellular therapy, including use of mesenchymal stem cells, for preventing and treating radiation-induced morbidity and mortality, GVHD and other conditions associated with uncontrolled inflammation. They purport that allogenic or autologous MEMs can be administered to exposed or damaged organs to treat acute, subacute or chronic radiation-induced disorder.

Improved Method for Generating Epicardium from Human Pluripotent Stem Cells

UW–Madison researchers have developed a xenogeneic- and albumin-free protocol targeting key regulatory elements of the Wnt/β-catenin signaling pathway, thus simplifying the steps and components for deriving cardiomyocyte progenitors and epicardial cells from hPSCs.

The innovation is based in part on the researchers’ discovery that differentiation stage-specific modulation of canonical Wnt signaling is sufficient for efficient epicardial induction from hPSCs under chemically defined, albumin-free conditions. Activation of Wnt signaling induces mesodermal differentiation, while subsequent Wnt inhibition drives cardiac specification. Reactivation of Wnt in cardiac progenitors specifies epicardial cells. These cells retain many characteristics of primary epicardial cells, including formation of a polarized epithelial sheet, expression of key epicardial genes, Wilms' tumor suppressor protein 1 (WT1), TCF21, TBX18 and ALDH1A2, and the ability to undergo epithelial-to-mesenchymal transition to generate fibroblast and vascular smooth muscle lineages.

Advantageously, inhibition of TGFβ pathway signaling via culture in the presence of small molecules permits long-term maintenance of hPSC-derived epicardial cells in vitro.